[1]舒娜,姜波,史春生.视网膜静脉阻塞继发黄斑水肿患者黄斑中心凹下脉络膜厚度变化研究[J].眼科新进展,2021,41(2):154-157.[doi:10.13389/j.cnki.rao.2021.0032]
　SHU Na,JIANG Bo,SHI Chunsheng.Changes in subfoveal choroidal thickness in eyes with macular edema secondary to retinal vein occlusion[J].Recent Advances in Ophthalmology,2021,41(2):154-157.[doi:10.13389/j.cnki.rao.2021.0032]
点击复制

视网膜静脉阻塞继发黄斑水肿患者黄斑中心凹下脉络膜厚度变化研究/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
41卷
期数:
2021年2期
页码:
154-157
栏目:
应用研究
出版日期:
2021-02-05

文章信息/Info

Title:
Changes in subfoveal choroidal thickness in eyes with macular edema secondary to retinal vein occlusion
作者:
舒娜; 姜波; 史春生
230041　安徽省合肥市，安徽省第二人民医院中古友谊眼科中心
Author(s):
SHU Na; JIANG Bo; SHI Chunsheng
Department of Ophthalmology,Anhui No.2 Provincial People’s Hospital,Hefei 230041,Anhui Province,China
关键词:
黄斑中心凹下脉络膜厚度; 视网膜静脉阻塞; 黄斑水肿; 康柏西普
Keywords:
subfoveal choroidal thickness;  retinal vein occlusion;  macular edema;  conbercept
分类号:
R774
DOI:
10.13389/j.cnki.rao.2021.0032
文献标志码:
A
摘要:
目的　研究视网膜中央静脉阻塞（central retinal vein occlusion，CRVO）和视网膜分支静脉阻塞（branch retinal vein occlusion，BRVO）继发黄斑水肿(ME)患者黄斑中心凹下脉络膜厚度(subfoveal choroidal thickness，SFCT)的变化情况，并探讨单次玻璃体内注射康柏西普后的短期反应。方法　回顾性病例对照研究。选取2019年6月至2020年6月在我院接受治疗的31例视网膜静脉阻塞继发ME的初治患者，根据发病类型分为CRVO组（16例16眼）和BRVO组（15例15眼）。所有患者在确诊后均接受玻璃体内注射康柏西普治疗。分别在康柏西普注射前和注射后2周测量两组SFCT并比较。结果　CRVO组注射前患眼的SFCT为（319.73±19.28）μm，较对侧健眼［（255.13±16.15）μm］明显增厚，差异有统计学意义(P=0.000)；注射后2周患眼的SFCT迅速降为（283.33±21.61）μm,与注射前相比差异具有统计学意义(P=0.000)。BRVO组注射前患眼SFCT为（310.31±19.41）μm，较对侧健眼［（255.31±21.69）μm］明显增厚；注射后2周患眼的SFCT迅速下降为（266.56±16.30）μm，与注射前相比差异具有统计学意义(P=0.000)。康柏西普注射前后CRVO组患眼和BRVO组患眼之间的SFCT变化值差异无统计学意义(P=0.210)。结论　CRVO和BRVO继发ME患眼的SFCT均明显比对侧健眼增厚，并在玻璃体内注射康柏西普后短时间内明显变薄。
Abstract:
Objective　To investigate the changes in subfoveal choroidal thickness (SFCT) in patients with macular edema (ME) secondary to branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO), and to investigate the short-term response to a single intravitreal injection of conbercept.Methods　The retrospective case-control studies were performed. A total of 31 patients with RVO secondary to ME who were initially treated in our hospital from June 2019 to June 2020 were randomly selected and divided into the CRVO group (16 patients 16 eyes) and the BRVO group (15 patients 15 eyes) according to the incidence type. All patients received conbercept intravitreal injection. SFCT was measured before and 2 weeks after conbercept injection. Paired t test was performed to compare the SFCT of RVO eyes and fellow eyes, as well as the SFCT of pre-injection and post-injection. Independent t test was performed to compare the SFCT of BRVO eyes and CRVO eyes.Results　In the CRVO patients, the SFCT of the eye before injection was (319.73±19.28) μm, which was significantly thickened compared with that of the contralateral eye ［(255.13±16.15) μm］, with statistically significant difference (P=0.000). Two weeks after injection, the SFCT of the affected eye rapidly decreased to (288.33±21.61)μm, and the difference was statistically significant (P=0.000). In BRVO patients, the SFCT of the affected eye before injection was (310.31±19.41)μm, which was significantly thickened compared with that of the contralateral eye ［(255.31±21.69)μm］. Two weeks after injection, the SFCT of the affected eyes decreased rapidly to (266.56±16.30)μm, and the difference was statistically significant (P=0.000). There was no significant difference in SFCT changes between the CRVO group and the BRVO group before and after the conbercept injection (P=0.210).Conclusion　The SFCT of CRVO and BRVO secondary ME patients is significantly thicker than that of contralateral healthy eyes, and is significantly reduced in a short time after combercept injection.

参考文献/References:

［1］　KLEIN R,MOSS S E,MEUER S M,KLEIN B E.The 15-year cumulative incidence of retinal vein occlusion:the Beaver Dam Eye Study［J］.Arch Ophthalmol,2008,126(4):513-518.
［2］　HAYREH S S,ZIMMERMAN B,MCCARTHY M J,PODHAJSKY P.Systemic diseases associated with various types of retinal vein occlusion［J］.Am J Ophthalmol,2001,131(1):61-77.
［3］　SCOTT I U,VANVELDHUISEN P C,ODEN N L,IP M S,BLODI B A,HARTNETT M E,et al.Baseline predictors of visual acuity and retinal thickness outcomes in patients with retinal vein occlusion:Standard care versus corticosteroid for retinal vein occlusion study report 10［J］.Ophthalmology,2011,118(2):345-352.
［4］　EKI O,CHANG S,TSENG J J,BARILE G R,DELPRIORE L V,WEISSMAN H,et al.Intravitreal triamcinolone injection for treatment of macular edema secondary to branch retinal vein occlusion［J］.Retina,2005,25(7):851-855.
［5］　DU K F,XU L,SHAO L,CHEN C X,ZHOU J Q,WANG Y X,et al.Subfoveal choroidal thickness in retinal vein occlusion［J］.Ophthalmology,2013,120(12):2749-2750.
［6］　COBAN-KARATAS M,ALTANYAYCIOGLU R,ULAS B,SIZMAZ S,CANAN H,SARITURK C.Choroidal thickness measurements with optical coherence tomography in branch retinal vein occlusion［J］.Int J Ophthalmol,2016,9(5):725-729.
［7］　YUMUSAK E,ORNEK K,DIKEL N H.Comparison of choroidal thickness changes following intravitreal dexamethasone,ranibizumab,and triamcinolone in eyes with retinal vein occlusion［J］.Eur J Ophthalmol,2016,26(6):627-632.
［8］　PARK J,LEE S,SON Y.Effects of two different doses of intravitreal bevacizumab on subfoveal choroidal thickness and retinal vessel diameter in branch retinal vein occlusion［J］.Int J Ophthalmol,2016,9(7):999-1005.
［9］　NISHINAKA A,INOUE Y,FUMA S,HIDA Y,NAKAMURA S,SHIMAZAWA M,et al.Pathophysiological role of VEGF on retinal edema and nonperfused areas in mouse eyes with retinal vein occlusion［J］.Invest Ophthalmol Vis Sci,2018,59(11):4701-4713.
［10］　INOVA I,EHAK J,NEKOLOVA J,JIRASKOVA N,HALUZOVA P,EHAKOVA T,et al.Correlation between ischemic index of retinal vein occlusion and oxygen saturation in retinal vessels［J］.Am J Ophthalmol,2018,188（1）:74-80.
［11］　TSUI I,WILLIAMS B K J,KOK Y O,HEILWEIL G,SCHWARTZ S D.Reliability of ischemic index grading in common retinal vascular diseases［J］.Ophthalmic Surg Lasers Imaging Retina,2015,46(6):618-625.
［12］　PENG Y,ZHANG X,MI L,LIU B,ZUO C,LI M,et al.Efficacy and safety of conbercept as a primary treatment for choroidal neovascularization secondary to punctate inner choroidopathy［J］.BMC Ophthalmol,2017,17(1):87.
［13］　ZHENG F,GREGORI G,SCHAAL K B,LEGARRETA A D,MILLER A R,ROISMAN L,et al.Choroidal thickness and choroidal vessel density in nonexudative age-related macular degeneration using swept-source optical coherence tomography imaging［J］.Invest Ophthalmol Vis Sci,2016,57(14):6256-6264.
［14］　BARDAK H,GUNAY M,BARDAK Y,ERCALIK Y.Retinal and choroidal thicknesses measured with swept-source optical coherence tomography after surgery for idiopathic macular hole［J］.Eur J Ophthalmol,2017,27(3):312-318.
［15］　BAEK J,LEE J H,JUNG B J,KOOK L,LEE W K.Morphologic features of large choroidal vessel layer:age-related macular degeneration,polypoidal choroidal vasculopathy,and central serous chorioretinopathy［J］.Graefes Arch Clin Exp Ophthalmol,2018,256(12):2309-2317.
［16］　JAP A,CHEE S P.The role of enhanced depth imaging optical coherence tomography in chronic Vogt-Koyanagi-Harada disease［J］.Br J Ophthalmol,2017,101(2):186-189.
［17］　GUPTA C,TAN R,MISHRA C,KHANDELWAL N,RAMAN R,KIM R,et al.Choroidal structural analysis in eyes with diabetic retinopathy and diabetic macular edema-A novel OCT based imaging biomarker［J］.PLoS One,2018,13(12):e0207435.
［18］　LEE E K,HAN J M,HYON J Y,YU H G.Changes in choroidal thickness after intravitreal dexamethasone implant injection in retinal vein occlusion［J］.Br J Ophthalmol,2015,99(11):1543-1549.
［19］　RAYESS N,RAHIMY E,YING G S,PEFKIANAKI M,FRANKLIN J,REGILLO C D,et al.Baseline choroidal thickness as a short-term predictor of visual acuity improvement following antivascular endothelial growth factor therapy in branch retinal vein occlusion［J］.Br J Ophthalmol,2019,103(1):55-59.
［20］　TANG F,XU F,ZHONG H,ZHAO X,LV M,YANG K,et al.Comparison of subfoveal choroidal thickness in eyes with CRVO and BRVO［J］.BMC Ophthalmol,2019,19(1):133.
［21］　REHAK J,REHAK M.Branch retinal vein occlusion:Pathogenesis,visual prognosis,and treatment modalities［J］.Curr Eye Res,2008,33:111-131.

相似文献/References:

[1]王刚.曲安奈德联合氪激光治疗视网膜静脉阻塞的临床疗效观察[J].眼科新进展,2013,33(7):000.
[2]马宇 刘意 郭娟 周利晓.金纳多联合血栓通对视网膜静脉阻塞患者同型半胱氨酸水平的影响[J].眼科新进展,2013,33(9):000.
[3]袁子茗 王帅 宋蓓雯 胡健艳 吴强.维速达尔光动力疗法诱导兔视网膜静脉阻塞的实验研究[J].眼科新进展,2012,32(9):000.
[4]李娟娟 李燕.先天性及获得性视盘血管袢的临床观察[J].眼科新进展,2013,33(11):000.
[5]陆秉文 吴星伟.视网膜静脉阻塞黄斑水肿患者玻璃体内注射ranibi-zumab后视野变化[J].眼科新进展,2013,33(12):000.
[6]金昱,石安娜,刘淼. 玻璃体内注射雷珠单抗（Ranibizumab）治疗视网膜静脉阻塞继发黄斑水肿[J].眼科新进展,2014,34(9):855.[doi:10.13389/j.cnki.rao.2014.0236]
[7]王媛,张金嵩,李秀娟.高度近视并发脉络膜新生血管患者黄斑中心凹下脉络膜厚度变化[J].眼科新进展,2015,35(10):949.[doi:10.13389/j.cnki.rao.2015.0258]
　WANG Yuan,ZHANG Jin-Song,LI Xiu-Juan.Changes of subfoveal choroidal thickness in high myopia with choroidal neovascularization[J].Recent Advances in Ophthalmology,2015,35(2):949.[doi:10.13389/j.cnki.rao.2015.0258]
[8]周洁,王宏彬,王文亭.雷珠单抗治疗视网膜静脉阻塞的临床研究[J].眼科新进展,2016,36(1):070.[doi:10.13389/j.cnki.rao.2016.0020]
　ZHOU Jie,WANG Hong-Bin,WANG Wen-Ting.Efficacy of intravitreal injection of ranibizumab for retinal vein occlusion[J].Recent Advances in Ophthalmology,2016,36(2):070.[doi:10.13389/j.cnki.rao.2016.0020]
[9]袁牧之,林颖,刘泉.视网膜静脉阻塞患者血浆和泪液中血管内皮生长因子表达的研究[J].眼科新进展,2016,36(5):468.[doi:10.13389/j.cnki.rao.2016.0125]
　YUAN Mu-Zhi,LIN Ying,LIU Quan.Expression of VEGF in plasma and tears of patients with RVO[J].Recent Advances in Ophthalmology,2016,36(2):468.[doi:10.13389/j.cnki.rao.2016.0125]
[10]王琛,李东豪,闻毅颐.玻璃体内注射康柏西普联合周边视网膜选择性光凝治疗视网膜静脉阻塞继发黄斑水肿的疗效及安全性[J].眼科新进展,2016,36(5):471.[doi:10.13389/j.cnki.rao.2016.0126]
　WANG Chen,LI Dong-Hao,WEN Yi-Yi.Intravitreal injection of conbercept combined with selective peripheral retinal photocoagulation for macular edema secondary to retinal vein occlusion[J].Recent Advances in Ophthalmology,2016,36(2):471.[doi:10.13389/j.cnki.rao.2016.0126]

备注/Memo

备注/Memo:
安徽省教育厅自然科学研究重点项目（编号：KJ2019A1097）；安徽省卫生厅科研计划项目（编号：2018SEYL025）；安徽省教育厅自然科学研究一般项目（编号：12925KJ2018B11）
更新日期/Last Update: 2021-02-05